Performant Healthcare, Inc. Announces Preliminary Financial Results for Second Quarter 2025
Performant will no longer hold its second quarter results conference call originally scheduled for Tuesday, August 5, 2025
Share
Second Quarter 2025 Results The Company currently expects to file its Form 10-Q for the quarter ended June 30, 2025 on August 7, 2025 and anticipates reporting second quarter revenues of approximately $37.8 million, net income of approximately $2.1 million, and adjusted EBITDA of approximately $6.2 million.
Transaction with Machinify
In a separate press release issued today, Performant announced its entry into a definitive agreement to be acquired by Machinify, a healthcare intelligence leader and portfolio company of New Mountain Capital. As a result, Performant will no longer hold its second quarter results conference call originally scheduled for Tuesday, August 5, 2025. Performant is also withdrawing its previously issued full-year 2025 guidance.
Note Regarding Use of Non-GAAP Financial Measures
In this press release, the Company presents adjusted EBITDA. This measure is not in accordance with accounting principles generally accepted in the United States of America ('US GAAP') and accordingly reconciliation of adjusted EBITDA determined in accordance with US GAAP is included in the 'Reconciliation of Non-GAAP Results' table at the end of this press release. We have included adjusted EBITDA in this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax, and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.
ABOUT PERFORMANT
Performant supports healthcare payers in identifying, preventing, and recovering waste and improper payments by leveraging advanced technology, analytics and proprietary data assets. Performant works with leading national and regional healthcare payers to provide eligibility-based, also known as coordination-of-benefits (COB) services, as well as claims-based services, which includes the audit and identification of improperly paid claims. Performant is a leading provider of these services in both government and commercial healthcare markets. Performant also provides advanced reporting capabilities, support services, customer care, and stakeholder training programs designed to mitigate future instances of improper payments.
To learn more about Performant, please visit www.performanthealthcare.com
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues, net income (loss), and adjusted EBITDA in 2025 and beyond. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: the Company's ability to generate revenue following long implementation periods associated with new customer contracts; client relationships and the Company's ability to maintain such client relationships; our commercial client growth strategy; many of the Company's customer contracts being subject to periodic renewal, not being exclusive, and not providing for committed business volumes; anticipated trends and challenges in the Company's business and competition in the markets in which it operates; the Company's indebtedness and compliance, or failure to comply, with restrictive covenants in the Company's credit agreement; opportunities and expectations for growth in the various markets in which the Company operates; the Company's ability to hire and retain employees with specialized skills that are required for its healthcare business; downturns in domestic or global economic conditions and other macroeconomic factors; the Company's ability to generate sufficient cash flows to fund our ongoing operations and other liquidity needs; the impact of public health emergencies, such as the COVID-19 pandemic, on the Company's business and operations, opportunities and expectations for the markets in which the Company operates; the impacts of a failure of the Company's operating systems or technology infrastructure or those of third-party vendors and subcontractors; the impacts of a cybersecurity breach or related incident to the Company or any of the Company's third-party vendors and subcontractors; the adaptability of the Company's technology platform to new markets and processes; the Company's ability to invest in and utilize data and analytics capabilities to expand our capabilities; the Company's growth strategy of expanding in existing markets and considering strategic alliances or acquisitions; the Company's ability to maintain, protect and enhance its intellectual property; expectations regarding future expenses; expected future financial performance; and the Company's ability to comply with and adapt to industry regulations and compliance demands.
More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2024 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox Sports
22 minutes ago
- Fox Sports
Celtics Minority Owner Reaches Deal to Buy WNBA's Sun for Record $325M
A group led by Boston Celtics minority owner Steve Pagliuca has reached a deal to buy the Connecticut Sun for a record $325 million and move the team to Boston, according to a person familiar with the sale. The franchise wouldn't play in Boston until the 2027 season. Pagliuca also would contribute $100 million for a new practice facility in Boston for the team, the person said. The person spoke to The Associated Press on condition of anonymity on Saturday because the deal hasn't been publicly announced. The sale is pending approval by the league and its Board of Governors. "Relocation decisions are made by the WNBA Board of Governors and not by individual teams," the league said in a statement. The Sun have played one regular-season game at TD Garden each of the last two years, including one against Caitlin Clark and the Indiana Fever in July. The league has announced five expansion teams that will begin play over the next five seasons, with Portland (2026), Toronto (2026), Cleveland (2028), Detroit (2029) and Philadelphia (2030) joining the WNBA. Each paid a then-record $250 million expansion fee. Nine other cities bid for expansion teams, including Houston, which the league singled out as getting a team in the future when it announced Cleveland, Detroit and Philadelphia in June. Boston did not. "No groups from Boston applied for a team at that time and those other cities remain under consideration based on the extensive work they did as part of the expansion process and currently have priority over Boston. Celtics' prospective ownership team has also reached out to the league office and asked that Boston receive strong consideration for a WNBA franchise at the appropriate time." The Boston Globe first reported the sale. The Sun are owned by the Mohegan Tribe, which runs the casino where the team has played since 2003. The Tribe bought the franchise for $10 million and relocated it from Orlando that year. The Connecticut franchise was the first in the league to be run by a non-NBA owner and also became the first to turn a profit. The team announced in May that it was searching for a potential buyer for the franchise and had hired investment bank Allen & Company to conduct the probe. The WNBA has experienced rapid growth in the last few seasons and ownership groups have been investing more into their teams, including player experiences. That has come in the way of practice facilities. The Sun are one of the few teams in the league that haven't announced any plans for a new training facility. Connecticut practices either at the arena in the casino or at a local community center. Despite the lack of facilities, the Sun have been one of the most successful teams in the league, making the postseason in 16 seasons, including a run of six straight semifinal appearances. But the team was hit hard this offseason with the entire starting five from last season leaving either via free agency or trade. Connecticut is currently in last place in the WNBA at 5-21. The team sent out a letter to season ticket holders last week saying they'd still be playing at the casino next year. The last team to be sold in the WNBA was in 2021 when real estate investor Larry Gottesdiener led a group that bought the Atlanta Dream for under $10 million. A year earlier, Mark Davis paid roughly $2 million for the Las Vegas Aces. Reporting by The Associated Press. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account, and follow leagues, teams and players to receive a personalized newsletter daily! FOLLOW Follow your favorites to personalize your FOX Sports experience Women's National Basketball Association Connecticut Sun Boston Celtics recommended Item 1 of 1 Get more from the Women's National Basketball Association Follow your favorites to get information about games, news and more
Business Wire
an hour ago
- Business Wire
RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
2 hours ago
- Yahoo
The Ocean Floor Could Power EVs. Will This Company Reap the Rewards?
Key Points The Metals Company is developing tech to harvest metal-rich nodules from the ocean floor. The company has no revenue and is still awaiting regulatory approval to begin mining. A recent U.S. permit application could offer The Metals Company an alternative path forward. 10 stocks we like better than TMC The Metals Company › Imagine diving into the Pacific Ocean's depths, not to see coral reefs or look for sunken pirate treasure, but to gather metal-dense rocks containing materials that can power the electric vehicle (EV) revolution. That, in a nutshell, is the bold vision of The Metals Company (NASDAQ: TMC), a Vancouver-based company aiming to vacuum polymetallic nodules from the seafloor. With a stock that had soared 430% in 2025 as of market close July 31, TMC has caught the eyes of investors betting on a future of green energy. But with no revenue, mounting losses, and a sea of risks, is this materials stock worth diving into? Let's explore. What does The Metals Company do? TMC isn't your typical mining stock. The company's core mission is to harvest polymetallic nodules from a remote stretch of Pacific Ocean known as the Clarion Clipperton Zone (CCZ). These lumpy, fist-sized seafloor stones are loaded with nickel, copper, cobalt, and manganese, all essential ingredients in everything from electric vehicle batteries to solar panels. On land, these rare earth metals are mined and processed in carbon-heavy ways, which ironically undercut the clean-tech future many are destined to be part of. TMC wants to flip the script. Instead of digging holes in the earth, it wants to scoop metal-rich nodules from the seabed and refine them into battery-grade materials, possibly with a lighter environmental footprint. The potential for TMC's mining operations is huge. As Henry Sanderson points out in his book Volt Rush: The Winners and Losers in the Race to Go Green, the deep sea holds more nickel, cobalt, and possibly other rare earth metals than all the world's land-based reserves combined. The CCZ alone is believed to contain some 21 billion metric tons of nodules -- enough raw material to not only shake China's grip on battery metals but supercharge the EV revolution for decades, if the materials can be gathered and refined. A big vision, but zero revenue But let's not sugarcoat it: TMC is nowhere near harvesting nodules at a commercial scale. The company reported zero revenue in the first quarter of 2025, paired with a net loss of about $20.6 million. That loss widened from $16.1 million in the quarter before. It turns out that building an underwater mining infrastructure from scratch isn't going to be cheap. Or quick. As of writing, TMC still doesn't have the green light to mine commercially in the CCZ. Although it holds exploration rights across two massive patches there, it doesn't yet have permission to start harvesting the goods. That authority rests with the International Seabed Authority (ISA), a United Nations-backed body that still hasn't finalized the regulatory playbook that companies like TMC need to operate. But there's a plot twist with the ISA: The U.S. never ratified the treaty that made the agency. While 169 nations and the European Union formally recognize the agency's authority, the U.S. isn't one of them. True, it does acknowledge parts of the treaty as international law, but technically, it's not bound by the ISA's rulebook. This means that if national interest comes into play -- say, securing domestic access to critical minerals -- the U.S. could try to go its own way. That would give companies like TMC a potential fast track to start operating in the CCZ. This is exactly the door that TMC is trying to walk through. In April 2025, the company filed a permit application under a decades-old U.S. law just days after President Donald Trump signed a U.S. executive order renewing interest in offshore critical minerals. If TMC's application is approved, it could mean mining under American jurisdiction in waters considered off-limits to the rest of the world. It's a long shot, legally speaking, and could breach international norms, but it would be a major breakthrough for a company with no revenue. A long-term wager with caveats TMC is what I'd call a moonshot (or, maybe a deep-sea Hail Mary) -- it's a big idea with big risks and potentially big payoffs. If the permits come through and the tech scales, today's price could look like a bargain. After all, a $2.65 billion market cap could look small compared to the multitrillion-dollar demand for battery metals that's expected over the next few decades. If TMC becomes even a minor supplier in that chain, its top-line growth could dwarf what investors are paying today. But if the ISA blocks its permit, or if U.S. jurisdiction doesn't hold up to legal scrutiny, or if other things turn out in ways not the best for the company, TMC could keep burning cash with no clear path to revenue. That's a lot of "ifs." Clearly, this isn't a stock for the risk-averse. For aggressive investors with long-term horizons, a small stake might make sense as part of a diversified portfolio. But I would wait for tangible progress, like a confirmed mining license, before scaling up exposure. Should you buy stock in TMC The Metals Company right now? Before you buy stock in TMC The Metals Company, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TMC The Metals Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Steven Porrello has positions in TMC The Metals Company. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The Ocean Floor Could Power EVs. Will This Company Reap the Rewards? was originally published by The Motley Fool Sign in to access your portfolio
